ArticleNanoscale research letters2020
Nano-clays as Potential Pseudo-antibodies for COVID-19.
Article in Nanoscale research letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Application of nanoparticles in antibody drug delivery.Frontiers in bioengineering and biotechnology · 2026Review
- Clay microparticles for the enhancement of bone regeneration: in vitro studies.Histochemistry and cell biology · 2023Article
- Presence and persistence of SARS-CoV-2 in aquatic environments: A mini-review.Current opinion in environmental science & health · 2022Review
- Immunology and controlling of coronaviruses; the current enemy for humanity: A review.International journal of biological macromolecules · 2021Review
- The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients.Polymers · 2021Review
- Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.Expert opinion on drug delivery · 2021Article
- Niclosamide encapsulated in mesoporous silica and geopolymer: A potential oral formulation for COVID-19.Microporous and mesoporous materials : the official journal of the International Zeolite Association · 2021Article
- Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Viability of SARS-CoV-2 in river water and wastewater at different temperatures and solids content.Water research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite several efforts, the development of an effective vaccine for COVID-19 may take a much longer time. Traditional/natural medicine, already experienced by humans, could be an earlier solution. Considering the research team's experience in using nano-clays as high-affinity material for cancer metastasis, melanoma treatment, and bone regeneration, we propose to use these nano-clays for the prevention/treatment of COVID-19. Owing to high affinity, nano-clays would capture the viruses before the latter get engaged with human hACE2. In this study, molecular-level simulations and modeling of the interaction of coronavirus spike and hACE2 proteins were performed with and without nano-clays. The results showed a very high level of affinity/cohesiveness among SARS-CoV-2 spike and nano-clays as compared to the one between the former and hACE2. We premise that these nano-clays since already being used as drug carriers could also be injected as "clays-alone" medicine. Recommendations have also been provided for future in vitro and in vivo studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.